Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04089449 · ClinicalTrials.gov registry record · Phase 1

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

A Phase 1 study of Advanced Solid Tumor and Recurrent Glioma, sponsored by Prelude Therapeutics.

Completed
Registry status
Phase 1
Development phase
86
Enrollment target
11
Study locations

NCT04089449: Completed Phase 1 study of Advanced Solid Tumor and Recurrent Glioma, sponsored by Prelude Therapeutics.

NCT04089449 is a Phase 1 study of Advanced Solid Tumor and Recurrent Glioma that has completed, run by Prelude Therapeutics. The registered enrollment target is 86 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04089449, a Phase 1 study of Advanced Solid Tumor and Recurrent Glioma, has completed, sponsored by Prelude Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
86 participants
Enrollment target
11
Study locations

Study Summary

This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.

Primary Outcome

Dose limiting toxicities will be evaluated through the first cycle

Conditions Studied

Advanced Solid Tumor Recurrent Glioma

Interventions

  • DRUG PRT811

Study Locations (11)

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Connecticut

  • Yale- New Haven Hospital- Yale Cancer Center - New Haven

Delaware

  • Christiana Care Health Services, Christiana Hospital - Newark

Florida

  • Florida Cancer Specialists - Lake Mary

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Illinois

  • Northwestern Memorial Hospital - Chicago

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Missouri

  • Washington University School of Medicine - Siteman Cancer Center - St Louis

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2019-11-06
Est. Completion 2023-03-28
Phase Phase 1
Prelude Therapeutics

12 total trials

What the finished NCT04089449 record still lists

NCT04089449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PRT811 is the first listed.

NCT04089449 lists 11 locations in 11 states (Colorado, Connecticut, Delaware).

Frequently Asked Questions

What is clinical trial NCT04089449 about?

NCT04089449 is a clinical study titled "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas". This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequ...

What is the current status of trial NCT04089449?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2019-11-06. Estimated completion is 2023-03-28.

What conditions does trial NCT04089449 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Recurrent Glioma.

What interventions are being tested in trial NCT04089449?

The interventions under investigation include: PRT811 (DRUG).

Who is sponsoring clinical trial NCT04089449?

This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04089449 being conducted?

This trial has 11 study locations across Colorado, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04089449's enrollment target sits among peer trials

86 130th of 189 higher than 58 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04089449, the US trial registry maintained by the National Library of Medicine. NCT04089449 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.